Analyzing POPs in 50 μL of Blood Samples
Scientists from SGC Environmental Services in Wilmington, North Carolina, USA, have demonstrated the development and validation of a method for the analysis of five persistent organic pollutants (POPs) from 50 ?L dried blood spots. The work was presented as a poster at Dioxin 2014, held in Madrid, Spain, from 31 August to 5 September.
Scientists from SGC Environmental Services in Wilmington, North Carolina, USA, have demonstrated the development and validation of a method for the analysis of five persistent organic pollutants (POPs) from 50 μL dried blood spots. The work was presented as a poster at Dioxin 2014, held in Madrid, Spain, from 31 August to 5 September.1
Isotope dilution with single-ion monitoring gas chromatography coupled with high-resolution mass spectrometry (ID–SIM–GC HRMS) analysis was performed on 72 samples of human whole blood to detect PCBs 101, 105, 138; PBB-153; and lindane. The first validation study found issues with high background from blank paper samples, which was reduced by cleaning with a carbon dioxide regimen. The second validation study was more successful with recoveries ranging from 51% for lindane to 100% for PBB-153.
The Column asked Vining if he had advice for others wanting to use DBS: “Yes, primarily that I think labelled spikes should be applied to the paper before they are sent to the field, somewhat analogous to the spikes put into EPA Method 23 air traps before they are sent to the field, albeit for a different reason. In this case, the spikes would allow an assessment of extraction efficiency, apart from that offered by the usual extraction standards. That way, the lab can assess how well the extraction standards are integrated with the sample.” He added: “It remains to be seen how far and how energetically this will be driven, but I think the technology is exciting, and the obstacles we’ve seen can presumably be dealt with.”
Reference
1. B. Vining et al., Poster “Analysis of POPs from 50 μL Dried Blood Spots “ presented at Dioxin 2014: http://bit.ly/1yjfKx7
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
